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By taking advantage of the extreme stability of a pro-
tein-DNA complex, we have obtained two highly specific
monoclonal antibodies against a predetermined palin-
dromic DNA sequence corresponding to the binding site
of the E2 transcriptional regulator of the human papil-
lomavirus (HPV-16). The purified univalent antibody
fragments bind to a double-stranded DNA oligonucleo-
tide corresponding to the E2 binding site in solution
with dissociation constants in the low and subnanomo-
lar range. This affinity matches that of the natural DNA
binding domain and is severalfold higher than the affin-
ity of a homologous bovine E2 C-terminal domain
(BPV-1) for the same DNA. These antibodies discrimi-
nate effectively among a number of double- and single-
stranded synthetic DNAs with factors ranging from 125-
to 20,000-fold the dissociation constant of the specific
DNA sequence used in the immunogenic protein-DNA
complex. Moreover, they are capable of fine specificity
tuning, since they both bind less tightly to another
HPV-16 E2 binding site, differing in only 1 base pair in a
noncontact flexible region. Beyond the relevance of ob-
taining a specific anti-DNA response, these results pro-
vide a first glance at how DNA as an antigen is recog-
nized specifically by an antibody. The accuracy of the
spectroscopic method used for the binding analysis sug-
gests that a detailed mechanistic analysis is attainable.
Unveiling the molecular rules for protein-DNA recognition is
a necessary step for the understanding of gene function and
regulation. A large number of proteins and cognate DNA se-
quences displaying a large variety of natural structures and
recognition modes have been and are being identified as in-
volved in physiological and pathological mechanisms (1, 2). In
addition, the ability to design new DNA binding activities
constitutes a major scientific challenge with technological ap-
plications such as control of gene function, gene therapy, ge-
nome research, and diagnostics.
Antibodies that bind to DNA are a hallmark of the autoim-
mune disease in systemic lupus erythematosus (3), but these
are not specific to particular sequences of single- or double-
stranded DNA, or at least the putative specific sequences that
elicit them have not been yet identified. Although a number of
natural anti-DNA antibodies have been described, DNA is
known to be a poor immunogen (4), and it has been virtually
impossible to generate antibodies against a specific DNA se-
quence to date. DNA binding antibodies were obtained using
phage display technology, but these bound to repetitive, non-
specific sequences (5). A chimeric sequence-specific DNA bind-
ing antibody was engineered by incorporating the DNA binding
domain of a transcription factor into the CDR3 of the heavy
chain (HCDR3) from a recombinant Fab molecule (6). This
elegant engineering approach can be further exploited through
antibody display in phage, but it cannot take advantage of the
natural diversity of antibody repertoires. Other approaches for
obtaining novel DNA binding activities arise from the combi-
nation of phage display technology in a zinc finger framework
(7); some of these chimeras bind DNA in the low nanomolar
range as judged by electrophoretic methods (8). A major goal for
generating sequence specific anti-DNA activities is the intra-
cellular expression of the resulting protein for control of gene
function (9).
Can antibodies be raised against specific and predetermined
DNA sequences? If so, how might such antibodies interact with
the DNA compared with natural DNA binders? In an attempt
to answer these questions, we used a natural protein-DNA
complex, the DNA binding domain of the human papillomavi-
rus E2 protein (E2C) bound to its target DNA (10), as immuno-
gen. This domain shows a particular dimeric b-barrel topology
consisting of an eight-stranded (four per subunit) b-barrel,
with major DNA binding and minor a-helices, packed against
opposite sides of the barrel (11). Based on the large stability of
the E2C-DNA complex (12), we used it as the antigen to pro-
duce a specific anti-DNA response against this key viral regu-
latory DNA binding site. We characterize two newly obtained
sequence-specific anti-DNA antibodies (a-DNAbs)1 using an
accurate spectroscopic method in solution.
MATERIALS AND METHODS
Anti-DNA Monoclonal Antibodies—The C-terminal DNA binding do-
main of the E2 protein from human papillomavirus strain-16 was
expressed in BL21-DE3 Escherichia coli cells as described previously
(13). The sequence of the A chain of the synthetic oligonucleotide is
59-GTAACCGAAATCGGTTGA-39, corresponding to E2 site 35 in the
HPV-16 genome, where the underlined sequence indicates the consen-
sus E2 binding site. A protein-DNA complex was formed by mixing E2C
and DNA at a 1:1 ratio. Details of the immunization will be described
elsewhere. Briefly, BALB/c mice were immunized intraperitoneally
with 25 mg of protein-DNA 1:1 complex emulsified in MPLt 1 TDM
Adjuvant System (Sigma). Second and third boosters were adminis-
tered intraperitoneally at 20-day intervals using similar doses. The
immune response elicited was monitored by indirect ELISA using the
18-bp oligonucleotide and the protein-DNA complexes as antigens, as
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described below. Final boosting involved an intraperitoneal injection of
20 mg of protein-DNA 1:1 complex dissolved in TBS (25 mM Tris, 150 mM
NaCl, pH 7.4) 4 days prior to the somatic cell hybridization. Spleeno-
cytes obtained from the immunized mouse with the highest anti-DNA
titer were fused with a NSO mouse plasmacytoma cell line following
established techniques (14). For the selection of anti-DNA antibodies
we used the site 35 double-stranded oligonucleotide as antigen (1 mg/
well in TBS). Of 92 culture supernatants screened after the fusion, eight
displayed anti-site 35 DNA reactivity. Two hybridomas producing anti-
DNA monoclonal antibodies (ED-10 and ED-84) were expanded and
isotyped as IgG1 by ELISA. Ascites fluids were produced and IgGs and
their derived Fab fragments prepared following standard procedures
(15). An additional gel chromatography step was included to ensure
that only univalent and highly purified Fab fragments were present.
The variable regions of both antibodies were cloned (16) and according
to their VH sequences, they belong to the J558 superfamily, shared by
several pathogenic autoimmune anti-DNA antibodies (17) (Fig. 1B).
Electrophoretic Mobility Assays—A site 35 DNA solution of 3 mM was
incubated with the different proteins at different ratios, and the con-
centrations were determined from the respective molar extinction coef-
ficients. A 6% acrylamide native gel was run in 0.1 M MOPS/Imidazol,
pH 6.5, at 5 V cm21 and the bands visualized by standard ethidium
bromide staining. Overall, the EMSA experiments in our simplified
buffer conditions (0.2 M NaCl, 25 mM Bis-Tris HCl, pH 7.0, 1 mM
dithiothreitol, and 10% glycerol for loading) appear to be dissociating,
and relative affinities cannot be inferred from these type of experiments
(18). Oligonucleotides were purchased from Integrated DNA Technolo-
gies (Coralville, IA).
Quantitative ELISA Binding—A quantitative ELISA assay for the
determination of the KD was carried out as described previously (19).
Briefly, ELISA plates were coated with streptavidin (1 mg/well in TBS)
for 60 min. After blocking with 1% BSA in TBS (BSA/TBS), 5 ng/well of
a 59-biotinylated site 35 DNA in BSA/TBS was added to the plate and
further incubated for 15 min. ED-10 or ED-84 IgGs were incubated at
0.8 nM concentration with different concentrations of site 35 oligonu-
cleotide solution in BSA/TBS. The 300-ml sample was incubated in
microcentrifuge tubes for 30 min at room temperature. The entire
mixture was transferred to the biotinylated DNA-coated ELISA plates
for 60 min and subsequently washed three times with TBS. The reten-
tion of a-DNAb IgGs in the solid phase, representing the degree of
binding to the biotinylated specific DNA, was developed using an anti-
IgG peroxidase-conjugated polyclonal antibody. For each separate tube,
the same mixture was incubated in the absence of biotinylated oligo-
nucleotide as a blank. The resulting A at 492 nm value was used to
calculate the antibody bound fraction, y. The data were linearized
according to Klotz: 1/y versus 1/Ag concentration (19). KD values were
obtained from the slope of the plot.
Fluorescence Binding Experiments—Fluorescence spectra were car-
ried out using an Aminco Bowman Series 2 instrument. Excitation
wavelength was fixed at 295 nm and the emission registered from 310
to 410 nm. Buffer base lines were subtracted. Tryptophan fluorescence
titrations were carried out with excitation at 295 nm, monitoring the
emission at 340 nm. The proteins were incubated in TBS in 3.0 ml
volumes at 25 6 0.1 °C, with protein concentration ranging from 5 to
100 nM, depending on the sequence used (see Table I and Fig. 4). DNA
oligonucleotides were gradually added, and the tryptophan fluorescence
was measured after 5 min equilibration at each point. The maximum
dilution was 10%, and the fluorescence was corrected accordingly. The
data were fitted to a simple binding model where both protein and DNA
concentrations are considered (20).
RESULTS
Generation of High Affinity Anti-DNA Antibodies—Using the
HPV16-E2C-site 35 DNA complex as immunogen, we obtained
a set of monoclonal antibodies against the E2C protein as well
as antibodies that reacted against the free or E2C bound DNA
but not with the protein (Fig. 1 and see “Materials and Meth-
ods”). We focused our studies on two selected a-DNAbs, ED-10
and ED-84, which showed reactivity in ELISA assays toward
the HPV-16 site 35 double-stranded DNA oligonucleotide ei-
ther free or bound to the HPV-16 E2C domain (Fig. 1A). These
antibodies also recognize the DNA when bound to the bovine
(BPV-1) E2C domain.
We cloned the variable regions of the two a-DNAbs antibod-
ies, and the amino acid sequence analysis indicates hypermu-
tation in the VH domains. In addition, the surprisingly identi-
cal CDR3s of the VH domain suggest a strong antigen-driven
selection (Fig. 1B). These CDR3s show no sequence homology to
any antibody described in data banks. Contrary to previously
reported for germ line gene J558-derived anti-DNA antibodies,
there is not an evident predominance of positively charged
residues in the a-DNAbs as the main source for binding affinity
as discussed elsewhere (21). Both a-DNAbs have different VL
chains, explaining at least in part the fine differences in
specificity.
Analysis of DNA Binding by the Antibodies—The interaction
of the a-DNAbs with the E2 site 35 oligonucleotide was prelim-
inary analyzed by an EMSA. No shift, and therefore no detect-
able binding, appeared when the EMSA was performed using a
radioactively phosphorylated oligonucleotide (not shown).
Thus, we used an unmodified oligonucleotide and developed the
bands using ethidium bromide staining. Fig. 2A shows the
result of such a binding experiment where the two Fabs, ED-10
and ED-84, produced a band shift as expected from the initial
ELISA assays. The absence of a band shift using radioactively
phosphorylated oligonucleotide strongly suggest that DNA
binding by both antibodies is sensitive to the phosphorylation
at the 59 terminus of the oligonucleotide (see below). Incremen-
tal additions of a-DNAb to the free DNA produce a gradual
band shift to the antibody-bound form as shown in Fig. 2B.
However, no reliable quantitative binding analysis would be
possible (see “Materials and Methods”).
The binding was quantitatively analyzed by competition
FIG. 1. Characterization of two anti-DNA monoclonal antibod-
ies. A, ELISA reactivity of ED-10 (open bars) and ED-84 (filled bars)
anti-DNA IgGs toward the different antigens, where DNA refers to E2
binding site 35 in HPV-16 genome (see above). Serum from a nonim-
munized mouse was used as a negative control (shaded bars). The
anti-DNA IgGs did not react toward a panel of control protein antigens,
and none of the specific free or E2C-bound DNA antigens were recog-
nized by a control antibody. B, comparison of the amino acid sequences
of the VH and VL CDR regions of the newly obtained a-DNAbs with their
corresponding germ line sequences (17, 25, 26). VH germ line sequences
analysis indicates they belong to the J558 family, used by several
pathogenic autoimmune anti-DNA antibodies (17). They present a total
HCDR3 homology and hypermutation, suggesting a marked antigen-
driven selection.
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ELISA in solution (19) and yield dissociation constants of
1.85 6 0.05 and 1.69 6 0.18 nM for ED-10 and ED-84, respec-
tively (Fig. 2C). This is the first strong indication that the
affinity of both antibodies for the E2 site 35 DNA is very high.
Nevertheless, we wanted to test a spectroscopic method that
would confirm the tight binding and provide the highest accu-
racy in solution.
The tryptophan fluorescence of the purified Fabs is quenched
by 30–40% upon binding to the DNA oligonucleotide, depend-
ing on the antibody (Fig. 3A). The DNA does not quench the
spectrum of a control Fab that recognizes the E2C protein (Fig.
3A). We carried out equilibrium titration experiments in solu-
tion monitored by tryptophan fluorescence. Titration of site 35
double-stranded DNA with ED-10 and ED-84 Fabs confirms
high affinity-saturable binding and a clear 1:1 stoichiometry,
as expected from univalent Fabs (Fig. 3B).
For an accurate determination of the dissociation constants
(KD) for DNA binding, we carried out tryptophan fluorescence
binding experiments at near-dissociation conditions for both
antibodies. A typical DNA binding experiment for ED-10 is
shown in Fig. 3C. Such analysis yielded dissociation constants
of 0.73 6 0.07 and 2.5 6 0.4 nM for ED-10 and ED-84, respec-
tively (Table I). The affinity of the same site 35 DNA oligonu-
cleotide for the E2C domain, the natural partner, is 0.2 nM (18).
Sequence Discrimination—The untranslated regulatory re-
gion of the HPV16 genome contains three similar, but not
identical, high affinity E2 binding sites. To test whether our
anti-site 35 DNA antibodies were capable of fine specificity
tuning as the E2C domain, we analyzed the binding of the
a-DNAbs to another natural E2 binding site, site 7450 (Fig.
4A). Both antibodies are able to discriminate HPV-16 E2 site
7450 from site 35 with 2–3-fold lower affinity (Table I).
In fluorescence binding experiments, phosphorylation of site
35-18 bp produced an increase in KD of 20- and 50-fold for
ED-10 and ED-84 Fabs, respectively (Table I), in agreement
FIG. 2. Binding of ED-10 and ED-84 to site 35 DNA. A, electro-
phoretic mobility shift assay. Site 35 DNA at 3 mM (Free, first lane) was
incubated with 4-fold either ED-10 (second lane) or ED-84 Fabs (third
lane) for 30 min at room temperature as described under ‘Materials and
Methods,‘ prior to gel loading. B, same as A. Site 35 DNA at 3 mM was
incubated with increasing amounts of a-DNAbs (0–12 mM). ED-10 was
shown as an example. Running conditions and gel staining are ex-
plained under “Materials and Methods.” C, quantitative ELISA binding
experiment. The binding of the a-DNAb IgGs (1.6 nM per site) to the
DNA-coated plate was prevented by incubation with increasing
amounts of free site 35 DNA, and the resulting optical density decrease
is a measure of the binding (inset). The data were transformed and
plotted as 1/y against 1/Ag (Klotz), and the KD was obtained from the
slope, after linear regression analysis (see “Materials and Methods”).
FIG. 3. DNA binding by fluorescence spectroscopy. A, fluorescence
spectral change upon binding of DNA. Proteins were incubated at 2 mM
concentration in TBS buffer, pH 7.4, and the spectra were recorded prior
and after addition of 2.5 mM site 35 DNA. The spectra of ED-84 Fab were
shown as an example, no addition (open squares), plus DNA (closed
squares). As a control, we used an anti-E2C Fab, ED-5: open circles, no
addition; closed circles, plus DNA. B, a stoichiometric titration was carried
out for both a-DNAbs (ED-10 shown in the figure), at 200 nM protein
concentration, monitoring fluorescence upon addition of site 35 DNA, as
described under “Materials and Methods.” C, the dissociation constants,
KD, were determined in titration experiments at near-dissociation condi-
tions. The figure shows the titration of ED-10 Fab, at 5 nM concentration.
The data were fitted as described under “Materials and Methods,” and the
residuals are shown (inset). The binding data of both antibodies to all the
sequences tested are shown in Table I.
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with preliminary EMSA experiments using radioactively phos-
phorylated site 35. Since the phosphorylation at the 59-OH
affects the binding of the a-DNAbs to the 18-bp site, we tested
a longer double-stranded oligonucleotide containing the E2 site
35. Table I shows that a 26-mer (site 35-26 bp) still binds with
high affinity, albeit lower than the 18-bp site by 1.3 and 0.4
kcal mol21, respectively, for each a-DNAb. The binding appears
to be weakened to a lesser extent when compared with phos-
phorylated site 35-18 bp. In addition, we analyzed the binding
of the a-DNAbs to a 36-bp site containing the other natural E2
site (7450), with both 59-OH ends modified with fluorescein
(FITC). Using tryptophan fluorescence quenching, we deter-
mined that the binding affinities are marginally modified with
respect to site 7450, marking a difference with the site 35 DNA,
which was used as immunogen. FITC fluorescence intensity
and anisotropy of site 7450-36 bp-FITC remain completely
unchanged after addition of a-DNAbs (not shown), suggesting
that in longer DNA stretches, the 59-OH is not involved in
recognition.
We determined the binding properties of purified Fab frag-
ments corresponding to both a-DNAbs to a set of different
palindromic and nonpalindromic double-stranded DNA oligo-
nucleotides of similar length (Fig. 4A). The affinities for most
sequences tested were markedly lower than the target se-
quence, with discrimination factors (KD, nonspecific/KD, site 35)
ranging from 125 to 20,000 (Fig. 4B and Table I). ED-84 binds
with 3-fold less affinity for specific DNA, but binds to most
nonspecific double- and single-stranded DNAs with higher af-
finity than ED-10. This suggests that the slightly lower affinity
of ED-84 for the specific DNA could eventually be linked to a
lower capacity of sequence discrimination ranging from 2- to
7-fold depending on the DNA sequence, evidenced in the ratio
of discrimination factors (DED-10/DED-84, see legend for Table I).
The discrimination factor for single-stranded site 35 DNA
was 20,500 and 3,000 for ED-10 and ED-84, respectively. Bind-
ing affinity for two nonspecific single-stranded DNAs was no-
ticeably higher, but since it is essentially a nonspecific inter-
action, we shall await detailed structural information to fully
understand the molecular basis of this phenomenon. In any
case, it should be pointed out that discrimination between
single- and double-stranded DNA in natural antibodies found
in autoimmune disease appears to be at the level of backbone
recognition (22), i.e. conformational, while the type of interac-
tion we are now describing is sequence-specific.
DISCUSSION
We have shown that it is possible to generate antibodies
against a desired and predetermined double-stranded DNA
sequence. The strong anti-DNA response generated could be
TABLE I
Sequence discrimination and affinity of a-DNAbs ED-10 and ED-84




a DDGb KD D DDG
nM kcal mol21 nM kcal mol21
dsDNAc
Site 35–18 bp 0.73 6 0.07 1 0 2.52 6 0.38 1 0
Site 35–26 bp 6.7 6 0.7 9.1 1.3 4.9 6 0.7 2.0 0.4
Site 35–18 bp-P 13.7 6 1.1 19 1.7 122 6 11 48 2.3
Site 7450–18 bp 2.1 6 1.1 2.9 0.6 5.6 6 1.6 2.2 0.5
7450–36 bp-FITC 5.7 6 1.6 7.8 1.2 3.31 6 1.8 1.3 0.2
ARC 158 6 0.3 217 3.1 344 6 0.6 136 2.9
CRE 208 6 0.2 285 3.2 316 6 0.3 125 2.8
EBNA 973 6 150 1333 4.2 1,200 6 153 476 3.6
VH mouse
d 1,526 6 244 605 3.8
HPV-16 2300 265 6 0.3 362 3.4 444 6 0.4 176 2.5
ssDNA
Site 35 15,100 6 8757 20561 5.8 7,570 6 2327 3004 4.7
ARC 895 6 109 1226 4.2 2,957 6 757 1173 4.2
HPV-16 2300 579 6 0.7 794 3.9 1,074 6 145 426 3.6
a The discrimination factor is the ratio KD, non-specific/KD, site 35–18.
b DG 5 2RT ln K; DDG 5 DGsite 35–18 2 DGDNAx.
c See legend of Figure 4A for details.
d This DNA displayed a very low affinity interaction, too difficult to fit to a single binding event.
FIG. 4. Sequence discrimination by the a-DNAbs. A, DNA se-
quences of various oligonucleotides tested for binding. Site 35, HPV-16
E2 site; site 7450, HPV-16 E2 site; ARC, the specific operator sequence
for the arc repressor; CRE, cyclic AMP-responsive element; EBNA,
Epstein-Barr nuclear antigen binding site; VH mouse, a randomly se-
lected mouse VH sequence; HPV-16 2300, an internal DNA sequence of
the HPV-16 genome. B, logarithmic plot of the binding of ED-84 Fab to
site 35 (open circles), single strand site 35 (closed circles), cyclic AMP-
responsive element (CRE) (closed triangles), VH mouse (open squares).
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the result of the high stability of the protein-DNA complex
conferring a longer lifetime to the DNA, possibly enhanced by
the high immunogenicity of the E2C protein. Further analysis
of the immune response to the E2C-DNA complex will be re-
quired to fully understand the process.
The fluorescence spectroscopic method developed allowed us
to evaluate the binding affinities with high accuracy and is
therefore promising when aiming at a full characterization of
the binding mechanism. Although the structural basis for this
change cannot be unequivocally assigned, the HCDR3s contain
a high proportion of aromatic residues as potential targets for
fluorescence quenching. We have shown that a classical phos-
phorylation-based EMSA missed the binding event, as it was
described for some protein-DNA interactions using filter assays
(23). The binding was physically confirmed by ELISA and
ethidium bromide-stained EMSA, which underestimate the
binding by at least 1 order of magnitude in our simplified assay
conditions (Fig. 2B and see “Materials and Methods”).
The monoclonal antibodies obtained display high specificity
and affinity approaching that of the natural DNA binding
domain E2C from the human infecting high risk strain, HPV-
16, determined in our laboratory by spectroscopic methods to
be 0.2 nM (18). The affinity of the highly related bovine (BPV-1)
E2C domain for the site 35 DNA oligonucleotide was recently
determined in our laboratory in similar buffer conditions and
was shown to be over 300-fold lower than the specific anti-site
35 DNA antibodies we now describe (18). On the other hand,
the a-DNAbs discriminate the HPV16 E2 binding site, 7450,
from site 35, used to raise the antibodies. The two sites are
almost identical, except for a single base change in a flexible
noncontact region. These two results are a clear indication of
the high affinity and sequence discrimination of the specific
a-DNAbs we describe, even for a minimal change in sequence.
The free 59-OH in the specific oligonucleotide appears to
participate in high affinity binding, but the difference in bind-
ing energies of phosphorylated species is well below the 3–5
kcal mol21 difference observed for nonspecific sequences. More-
over, the a-DNAbs bind tightly to the specific sequence con-
tained within longer DNA oligonucleotides and even to oligo-
nucleotides with 59-OH of both strands modified with FITC.
Binding of a site 7450 oligonucleotide of 36 bp is as tight as the
18-bp site 7450, suggesting that modifications in the 59-OH of
shorter oligonucleotides would interfere with the binding.
Without structural data, at this stage we can only speculate
about the origin of the effect of 59 phosphorylation, which could
in part be that it is recognized by the a-DNAb, but possible
effects on the DNA conformation or stability, particularly in an
18-bp palindrome, cannot be ruled out. This could also lead to
slow conformational changes that might affect the binding at
equilibrium. All the evidence accumulated so far strongly sug-
gests that the major determinant for binding is still the DNA
base sequence.
The fact that the a-DNAbs specifically bind to the E2 site 35
DNA oligonucleotide does not imply that they recognize the E2
consensus sequence, i.e. ACCGN4CGGT, in the same manner
as the viral domains. The a-DNAbs could well recognize part of
the conserved consensus sequence and part of the flexible non-
contact region, as the lower binding affinity for a related site
suggests. Alternatively, they may recognize bases outside the
consensus sequence of the synthetic site 35 DNA oligonucleo-
tide. The precise sequence binding requirements will be
mapped using a variety of synthetic oligonucleotides or hope-
fully uncovered by detailed structural analysis. The palin-
dromic nature of this oligonucleotide suggests a possible du-
plex-hairpin equilibrium in solution, but more evidence is
needed to ascertain the precise recognition motif.
It is hardly possible that the DNA recognition mechanism by
the a-DNAbs is similar to the natural DNA binding domain.
The latter binds the DNA at the surface, conferring a substan-
tial bent to it (11), while antibody binding sites frequently
display large flat and extended surfaces or deep cavities (24).
Furthermore, given the evident lack of positive charges at the
combining site of the antibodies, an electrostatic component as
high as that found in natural DNA-binding proteins is also
unlikely. Detailed atomic structures and thermodynamic bind-
ing analysis will shed light into this puzzling novel protein-
DNA recognition interface.
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